Article

(Photo = PRODIZEN)

[MD Today = Reporter Juseong Kim] Prodizen announced that it successfully concluded its participation in the 8th Annual Conference and International Symposium of the Korean Academy of Facial Contouring (KAFC 2026), held on June 21 at COEX in Seoul, where it actively engaged with medical professionals and shared the latest developments in regenerative medicine.

The Korean Academy of Facial Contouring (KAFC) serves as a platform for academic exchange, bringing together experts in lifting procedures, regenerative medicine, and aesthetic dermatology. This year’s conference was held under the theme “Everything About Lifting: From Fundamentals to Advanced Techniques”, attracting medical professionals from Korea and abroad.

At the conference, Prodizen operated an exhibition booth showcasing its PRP and regenerative medicine solutions. The company engaged in extensive discussions with attending physicians regarding clinical experiences, practical applications, and emerging trends in regenerative medicine. Many visitors expressed strong interest in autologous blood-based regenerative technologies, leading to active exchanges on product utilization and clinical know-how.

During the scientific program, Dr. Junho Choi and Dr. Jaehyung Kim of Hoan Clinic, long-standing clinical partners of Prodizen, participated as invited speakers and presented their latest clinical experiences and research findings in the field of autologous blood-based regenerative medicine.

Dr. Choi delivered a presentation titled “From Filling Volume to Restoring Biology: Clinical Expansion of Activated PRP-Derived Exosome Therapy.” His lecture highlighted the evolving paradigm of regenerative medicine, moving beyond conventional volume enhancement toward tissue regeneration and biological restoration, while exploring the clinical potential of activated PRP-derived exosome therapy.

Following this, Dr. Kim presented “New Horizons in Regenerative Medicine with Autologous Exosomes: From Mechanism to Clinical Application.” His lecture focused on the mechanisms of action and clinical applications of autologous blood-derived exosomes, presenting a vision for their expanding role and future potential within regenerative medicine.

The presentations demonstrated how autologous blood-based regenerative medicine is evolving beyond a supplementary treatment concept into a comprehensive therapeutic platform for tissue regeneration and functional restoration. The sessions received significant attention and positive feedback from attending physicians.

Through close collaboration with its clinical partners, Prodizen continues to support the advancement of autologous blood-based regenerative medicine by providing innovative technologies and solutions, while offering a variety of clinically applicable regenerative platforms.

A representative from Prodizen commented, “The KAFC conference provided a valuable opportunity to communicate directly with healthcare professionals, better understand their clinical needs, and exchange the latest insights in regenerative medicine. We will continue working closely with medical professionals to deliver safe, reliable, and effective regenerative medicine solutions.”

Prodizen is a regenerative medicine company that has been developing PRP-related technologies since the early stages of PRP commercialization in Korea. Leveraging its proprietary GMP-certified manufacturing facility, robust quality management system, and blood-based regenerative platform technologies, the company continues to expand its presence in both domestic and international healthcare markets.

The company has also strengthened its technological competitiveness through continuous research and development and the acquisition of proprietary technologies and patents. By maintaining close collaboration with healthcare professionals, Prodizen provides a broad range of products and solutions designed for practical clinical use.

Moving forward, Prodizen plans to continue advancing research and technological innovation in regenerative medicine while expanding its global market presence. Through ongoing collaboration with medical professionals and the development of innovative regenerative medicine technologies, the company aims to deliver meaningful value to healthcare providers and patients worldwide.